OTC Drug Review Hindered By Citizen Petition Proposed Rule - CHPA
This article was originally published in The Tan Sheet
FDA's proposal to ban citizen petitions on pending regulations "appear[s] to preclude the introduction of new data and information in the OTC drug review," the Consumer Healthcare Products Association argues in Feb. 28 comments.
You may also be interested in...
FDA is extending the OTC drug labeling implementation date to May 2002 to allow time for the agency to develop "forthcoming guidances" regarding a number of outstanding industry concerns.
Pending FDA actions cannot be the subject of a citizen petition submitted to the agency under a proposed rule published in the Nov. 30 Federal Register.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC